利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

351 条记录 (耗时 0.051 秒)

    Introduction of modifying agents into skin by electroporation
    1.
    发明授权
    Introduction of modifying agents into skin by electroporation 失效
    通过电穿孔将改性剂引入皮肤

    公开(公告)号：US5911223A

    公开(公告)日：1999-06-15

    申请号：US695367

    申请日：1996-08-09

    申请人： James C. Weaver ,  Tani Chen ,  Christopher Cullander ,  Richard Guy ,  Robert S. Langer ,  Thomas E. Zewert ,  Uwe Pliquett ,  Rita Vanbever ,  Mark R. Prausnitz

    发明人： James C. Weaver ,  Tani Chen ,  Christopher Cullander ,  Richard Guy ,  Robert S. Langer ,  Thomas E. Zewert ,  Uwe Pliquett ,  Rita Vanbever ,  Mark R. Prausnitz

    IPC分类号： A61B17/00 ,  A61N1/32 ,  A61B19/00

    CPC分类号： A61N1/0424 ,  A61N1/325 ,  A61B2017/00765 ,  A61N1/0428 ,  Y10S607/901

    摘要： A method of modifying epidermis for transport of a material by electroporation includes applying to epidermis an agent that, upon entry into the epidermis, will modify the epidermis to thereby cause and altered rate of transport of a material across the epidermis. Typically, the altered rate will be an increased rate of transport. The epidermis is electroporated, whereby at least a portion of the modifying agent enters the electroporated epidermis, thereby modifying the epidermis to cause an altered rate of transport of a material across the epidermis. In another embodiment, the modifying agent can modify the epidermis to enable measurement and/or monitoring of physiological conditions or change within or beneath the epidermis. The modifying agents can also be employed to facilitate discharge of fluids from within an organism, such as by providing pathways for discharge of fluids from a tumor. Examples of modifying agents include: oxidizing agents; reducing agents; particles, such as optical indicator beads or beads that include drugs to be released into tissue; electrically-charged particles or molecules; etc. Materials that can be transported by the method of the invention include, for example, proteins, nucleic acids, electrically charged molecules or particles, microorganisms suitable for immunization, etc. Also, tissues other than skin can be employed in the method of the invention.

    摘要翻译： 通过电穿孔来改变用于运输材料的表皮的方法包括向表皮施加一种在进入表皮时将改变表皮从而引起和改变材料穿过表皮的运输速率的试剂。 通常，改变率将是增加的运输速度。 表皮被电穿孔，由此至少一部分改性剂进入电穿孔表皮，从而改变表皮，导致材料穿过表皮的转运速率。 在另一个实施方案中，修饰剂可以修饰表皮以使得能够测量和/或监测生理条件或在表皮内或下表面的变化。 还可以使用改性剂来促进从生物体内排出流体，例如通过提供从肿瘤排出流体的途径。 改性剂的实例包括：氧化剂; 还原剂; 颗粒，例如包括要释放到组织中的药物的光学指示剂珠粒或珠粒; 带电粒子或分子; 可以通过本发明的方法传输的材料包括例如蛋白质，核酸，带电分子或颗粒，适合免疫的微生物等。另外，皮肤以外的组织可以用于 发明。

    Method for rapid temporal control of molecular transport across tissue
    3.
    发明授权
    Method for rapid temporal control of molecular transport across tissue 失效
    快速时间控制组织分子转运的方法

    公开(公告)号：US5667491A

    公开(公告)日：1997-09-16

    申请号：US487470

    申请日：1995-06-07

    申请人： Uwe Pliquett ,  Mark R. Prausnitz ,  James C. Weaver ,  Robert S. Langer

    发明人： Uwe Pliquett ,  Mark R. Prausnitz ,  James C. Weaver ,  Robert S. Langer

    IPC分类号： A61B5/00 ,  A61K38/38 ,  A61K38/48 ,  A61K41/00 ,  A61K48/00 ,  A61N1/32 ,  C07K14/82 ,  C12N15/87 ,  A61M31/00

    CPC分类号： A61N1/0412 ,  A61B5/14514 ,  A61B5/418 ,  A61K31/00 ,  A61K41/0047 ,  A61K48/00 ,  A61N1/325 ,  A61N1/327 ,  C07K14/82 ,  C12N15/87 ,  G01N33/50 ,  A61B5/14532 ,  A61N1/0452

    摘要： A method is disclosed for treating tissue in response to a stimulus generated by the tissue. In one embodiment, the method transdermally treats an organism in response to a stimulus. In this embodiment, the medication is applied to epidermis of the organism, and the epidermis is electroporated in response to a stimulus, whereby the medication passes through the epidermis at a rate sufficient to alter the stimulus, thereby transdermally treating the organism. In another embodiment, the method measures a blood component content of blood. A portion of epidermis is electroporated to cause an aqueous fluid to be directed through an electroporated epidermis to a surface of the epidermis. Thereafter, the blood component content of the aqueous fluid is measured for correlation with a known aqueous fluid blood component content associated with a known concentration of blood component in the blood. The blood component concentration of the blood can thereby be measured. In still another embodiment, the method includes directing a medication to the tissue which can alter the stimulus when the tissue is electroporated, and electroporating the tissue in response to a stimulus, whereby the medication passes through the tissue in an amount sufficient to alter the stimulus, thereby treating the organism.

    摘要翻译： 公开了一种响应于由组织产生的刺激来治疗组织的方法。 在一个实施方案中，所述方法响应于刺激经皮处理生物体。 在该实施方案中，将药物施用于生物体的表皮，并且响应于刺激而对表皮进行电穿孔，由此药物以足以改变刺激的速率通过表皮，从而透皮治疗生物体。 在另一个实施方案中，该方法测量血液的血液成分含量。 将一部分表皮电穿孔以使含水液体通过电穿孔表皮导入表皮表面。 此后，测量含水流体的血液成分含量与已知的血液中血液成分浓度相关的含水液体成分含量的相关性。 因此可以测量血液的血液成分浓度。 在另一个实施方案中，该方法包括将药物引导到组织，当组织被电穿孔时可以改变刺激，并响应于刺激电穿孔组织，由此药物以足以改变刺激的量通过组织 ，从而治疗生物体。

    Method for rapid temporal control of molecular transport across tissue
    4.
    发明授权
    Method for rapid temporal control of molecular transport across tissue 失效
    快速时间控制跨组织分子转运的方法

    公开(公告)号：US5547467A

    公开(公告)日：1996-08-20

    申请号：US096512

    申请日：1993-07-23

    申请人： Uwe Pliquett ,  Mark R. Prausnitz ,  James C. Weaver ,  Robert S. Langer

    发明人： Uwe Pliquett ,  Mark R. Prausnitz ,  James C. Weaver ,  Robert S. Langer

    IPC分类号： A61B5/00 ,  A61K38/38 ,  A61K38/48 ,  A61K41/00 ,  A61K48/00 ,  A61N1/32 ,  C07K14/82 ,  C12N15/87 ,  A61M37/00

    CPC分类号： A61N1/0412 ,  A61B5/14514 ,  A61B5/418 ,  A61K31/00 ,  A61K41/0047 ,  A61K48/00 ,  A61N1/325 ,  A61N1/327 ,  C07K14/82 ,  C12N15/87 ,  G01N33/50 ,  A61B5/14532 ,  A61N1/0452

    摘要： A method is disclosed for treating tissue in response to a stimulus generated by the tissue. In one embodiment, the method transdermally treats an organism in response to a stimulus. In this embodiment, the medication is applied to epidermis of the organism, and the epidermis is electroporated in response to a stimulus, whereby the medication passes through the epidermis at a rate sufficient to alter the stimulus, thereby transdermally treating the organism. In another embodiment, the method measures a blood component content of blood. A portion of epidermis is electroporated to cause an aqueous fluid to be directed through an electroporated epidermis to a surface of the epidermis. Thereafter, the blood component content of the aqueous fluid is measured for correlation with a known aqueous fluid blood component content associated with a known concentration of blood component in the blood. The blood component concentration of the blood can thereby be measured. In still another embodiment, the method includes directing a medication to the tissue which can alter the stimulus when the tissue is electroporated, and electroporating the tissue in response to a stimulus, whereby the medication passes through the tissue in an amount sufficient to alter the stimulus, thereby treating the organism.

    摘要翻译： 公开了一种响应于由组织产生的刺激来治疗组织的方法。 在一个实施方案中，所述方法响应于刺激经皮处理生物体。 在该实施方案中，将药物施用于生物体的表皮，并且响应于刺激而对表皮进行电穿孔，由此药物以足以改变刺激的速率通过表皮，从而透皮治疗生物体。 在另一个实施方案中，该方法测量血液的血液成分含量。 将一部分表皮电穿孔以使含水液体通过电穿孔表皮导入表皮表面。 此后，测量含水流体的血液成分含量与已知的血液中血液成分浓度相关的含水液体成分含量的相关性。 因此可以测量血液的血液成分浓度。 在另一个实施方案中，该方法包括将药物引导到组织，当组织被电穿孔时可以改变刺激，并响应于刺激电穿孔组织，由此药物以足以改变刺激的量通过组织 ，从而治疗生物体。

    Preparation of novel particles for inhalation
    7.
    发明授权
    Preparation of novel particles for inhalation 有权
    用于吸入的新型颗粒的制备

    公开(公告)号：US06652837B1

    公开(公告)日：2003-11-25

    申请号：US09394233

    申请日：1999-09-13

    申请人： David A. Edwards ,  Robert S. Langer ,  Rita Vanbever ,  Jeffrey Mintzes ,  Jue Wang ,  Donghao Chen

    发明人： David A. Edwards ,  Robert S. Langer ,  Rita Vanbever ,  Jeffrey Mintzes ,  Jue Wang ,  Donghao Chen

    IPC分类号： A61K912

    CPC分类号： A61K9/0075 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1641 ,  A61K9/1647 ,  A61K9/1658 ,  A61K31/135 ,  A61K31/137 ,  A61K38/28 ,  A61K38/38 ,  A61K47/6927 ,  Y10S514/958

    摘要： Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or negatively charged therapeutic agent and a charged molecule of opposite charge for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 &mgr;m and 30 &mgr;m, which together yield an aerodynamic diameter of the particles of between approximately one and three microns. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of a therapeutic or diagnostic agent and a surfactant. Surfactants can be incorporated on the particle surface for example by coating the particle after particle formation, or by incorporating the surfactant in the material forming the particle prior to formation of the particle. Exemplary surfactants include phosphoglycerides such as dipalmitoyl phosphatidylcholine (DPPC). The particles can be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide a variety of therapeutic agents. Formation of complexes of positively or negatively charged therapeutic agents with molecules of opposite charge can allow control of the release rate of the agents into the blood stream following administration.

    摘要翻译： 提供了将具有正或负电荷的治疗剂的表面活性剂和/或亲水或疏水配合物和用于药物递送至肺系统的带电分子的相反电荷的颗粒，以及用于其合成和给药的方法。 在一个优选的实施方案中，颗粒由可生物降解的材料制成，并且具有小于0.4g / cm 3的振实密度和5μm和30μm之间的质量平均直径，这两个颗粒之间的颗粒的空气动力学直径在 大约一到三微米。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如，颗粒可以由聚（乳酸）或聚（乙醇酸）或其共聚物形成。 或者，颗粒可以仅由治疗剂或诊断剂和表面活性剂形成。 表面活性剂可以结合在颗粒表面上，例如通过在颗粒形成之后涂覆颗粒，或者通过在形成颗粒之前将表面活性剂并入形成颗粒的材料中。 示例性表面活性剂包括磷酸甘油酯，例如二棕榈酰磷脂酰胆碱（DPPC）。 这些颗粒可以有效地雾化，用于给呼吸道施用以允许全身或局部递送各种各样的治疗剂。 正电荷或带负电荷的治疗剂与相反电荷分子的复合物的形成可以允许在给药后将药剂释放到血流中的释放速率。

    Preparation of particles for inhalation
    10.
    发明授权
    Preparation of particles for inhalation 失效
    吸入颗粒的制备

    公开(公告)号：US5985309A

    公开(公告)日：1999-11-16

    申请号：US971791

    申请日：1997-11-17

    申请人： David A. Edwards ,  Robert S. Langer ,  Rita Vanbever ,  Jeffrey Mintzes ,  Jue Wang ,  Donghao Chen

    发明人： David A. Edwards ,  Robert S. Langer ,  Rita Vanbever ,  Jeffrey Mintzes ,  Jue Wang ,  Donghao Chen

    IPC分类号： A61K9/16 ,  A61K31/135 ,  A61K31/137 ,  A61K38/28 ,  A61K38/38 ,  A61K13/00

    CPC分类号： A61K9/1647 ,  A61K31/135 ,  A61K31/137 ,  A61K38/28 ,  A61K38/38

    摘要： Particles incorporating a surfactant and/or a hydrophilic or hydrophobic complex of a positively or negatively charged therapeutic agent and a charged molecule of opposite charge for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the particles are made of a biodegradable material and have a tap density less than 0.4 g/cm.sup.3 and a mass mean diameter between 5 .mu.m and 30 .mu.m, which together yield an aerodynamic diameter of the particles of between approximately one and three microns. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of poly(lactic acid) or poly(glycolic acid) or copolymers thereof. Alternatively, the particles may be formed solely of a therapeutic or diagnostic agent and a surfactant. Surfactants can be incorporated on the particle surface for example by coating the particle after particle formation, or by incorporating the surfactant in the material forming the particle prior to formation of the particle. Exemplary surfactants include phosphoglycerides such as dipalmitoyl phosphatidylcholine (DPPC). The particles can be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of wide a variety of therapeutic agents. Formation of complexes of positively or negatively charged therapeutic agents with molecules of opposite charge can allow control of the release rate of the agents into the blood stream following administration.

    摘要翻译： 提供了将具有正或负电荷的治疗剂的表面活性剂和/或亲水或疏水配合物和用于药物递送至肺系统的带电分子的相反电荷的颗粒，以及用于其合成和给药的方法。 在优选的实施方案中，颗粒由可生物降解的材料制成，并且具有小于0.4g / cm 3的振实密度和5μm至30μm之间的质量平均直径，其一起产生颗粒的空气动力学直径在约 一和三微米。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如，颗粒可以由聚（乳酸）或聚（乙醇酸）或其共聚物形成。 或者，颗粒可以仅由治疗剂或诊断剂和表面活性剂形成。 表面活性剂可以结合在颗粒表面上，例如通过在颗粒形成之后涂覆颗粒，或者通过在形成颗粒之前将表面活性剂并入形成颗粒的材料中。 示例性表面活性剂包括磷酸甘油酯，例如二棕榈酰磷脂酰胆碱（DPPC）。 这些颗粒可以有效地雾化，用于给呼吸道施用以允许全身或局部递送各种各样的治疗剂。 正电荷或带负电荷的治疗剂与相反电荷分子的复合物的形成可以允许在给药后将药剂释放到血流中的释放速率。